Table 3 Univariate associations between baseline demographics and interval durationsa
Evaluation durations | Treatment duration | Total duration | ||||||
|---|---|---|---|---|---|---|---|---|
Symptom onset to definitive diagnostic study | Diagnostic study to confirmed diagnosis | Confirmed diagnosis to chemotherapy initiation | Symptom onset to chemotherapy initiation | |||||
Age | ||||||||
< 60 years | 105 [61–170.8] | 6 [3–8] | 19 [11–31] | 127 [85.5–211] | ||||
> 60 years | 99 [53–167] | p = 0.312 | 6 [4–9] | p = 0.445 | 21 [13–34.8] | p = 0.081 | 125 [84–182] | p = 0.278 |
Sex | ||||||||
Male | 101 [55.8–170] | 5 [3–8] | 20 [11–32] | 126 [84–194] | ||||
Female | 100 [55–166.5] | p = 0.644 | 6 [4–8.3] | p = 0.101 | 21.5 [11.3–36.8] | p = 0.516 | 127 [86–212.5] | p = 0.475 |
Living | ||||||||
Within Delhi Region | 107.5 [61–171] | 5 [4–9] | 19 [11–32] | 130.5 [87–201] | ||||
Outside Delhi | 92.5 [52–167] | p = 0.332 | 6 [3–8] | p = 0.998 | 21 [11–34] | p = 0.643 | 125 [83.5–197.5] | p = 0.482 |
Income | ||||||||
Above Poverty Lineb | 99 [62–169] | 6 [3–9] | 21 [12–36] | 131.5 [90–192] | ||||
Below Poverty Line | 97.5 [54.8–166.3] | p = 0.860 | 5 [3–7.3] | p = 0.091 | 16 [8.3–25.8] | p = 0.034 | 113 [68–216] | p = 0.247 |
Education | ||||||||
Primary education or less | 104 [64.5–171] | 6 [3–9] | 19 [11–35] | 127 [83–215.5] | ||||
Some High School or More | 99 [52.8–173] | p = 0.521 | 5 [3–8] | p = 0.254 | 21 [12–31.3] | p = 0.851 | 127 [84.8–205.8] | p = 0.617 |
Smoking Status | ||||||||
Never Smoker | 107.5 [57.8–172.5] | 6 [3–8] | 21 [10–32.5] | 136 [88.5–212.5] | ||||
Current Smoker | 91 [48.5–166.5] | 6 [3–9] | 19 [11–32] | 122 [72.5–186] | ||||
Previously Quit | 108 [62–171] | p = 0.131 | 5 [3.8–8] | p = 0.729 | 22 [12–35] | p = 0.462 | 126 [90–188.3] | p = 0.140 |
ECOG Performance Status | ||||||||
0 or 1 | 93 [51–167] | 5 [3–8] | 23 [13–35] | 125 [90–195] | ||||
2 or 3 | 99 [59.5–165.5] | 6 [4–10] | 19 [11–34] | 126 [79.3–186] | ||||
4 or 5 | 148 [90.5–199.3] | p = 0.275 | 4 [2.5–8.5] | p = 0.015 | 21.5 [15.8–67] | p = 0.140 | 156 [86.8–216.3] | p = 0.875 |
KPS Score | ||||||||
KPS >/ 70 | 98.5 [52.8–168] | 6 [3–8] | 21 [12–33] | 125 [84–193] | ||||
KPS < 70 | 106 [70.3–170.3] | p = 0.291 | 6 [4–9] | p = 0.149 | 21 [12–40] | p = 0.628 | 127 [90–213.5] | p = 0.227 |
Previous ATT History | ||||||||
Did not receive ATT | 83 [50–159] | 5 [3–8] | 19 [11–31] | 113 [75–180] | ||||
Received ATT | 150 [93–216] | p < .0001 | 5 [3–8] | p < 0.997 | 22 [11.5–36] | p = 0.093 | 187 [134–261.5] | p < .0001 |
Type of Definitive Biopsy | ||||||||
Bronchoscopy | 101 [53–167] | 6 [4–9] | 20 [12–32] | 126 [80.5–195.8] | ||||
CT-Guided Lung Biopsy | 107 [72–171] | 6 [4–8] | 22 [12.5–42.5] | 150 [96.3–227.3] | ||||
US-Guided Lung Biopsy | 83.5 [46.3–166] | 6 [4–8] | 20.5 [4.8–33.8] | 90 [60–180] | ||||
Thorascopy | 75 [49–140] | 5 [4–7] | 22 [8–34] | 103.5 [60–205] | ||||
Surgical | 83 [1 patient] | 13 [1–26] | 16 [1 patient] | N/A | ||||
Other | 88 [51–171] | p = 0.259 | 2 [1–6] | p = .0001 | 21 [9.5–30.5] | p = 0.480 | 124.5 [90–194] | p = 0.090 |
Histologic Diagnosis | ||||||||
NSCLC | 108 [65–172] | 5 [3–8] | 22 [12–35] | 133 [90–210.5] | ||||
SCLC | 75 [42–122] | p < .0001 | 7 [4–10] | p < .0001 | 15 [9–23] | p < .0001 | 94.5 [65–157.3] | p < .0001 |
NSCLC Stage at Diagnosis | ||||||||
Stage 1 | 90 [70.8–328.3] | 5 [4–9] | 63 [1 patient] | 151 [1 patient] | ||||
Stage 2 | 104.5 [74–172.3] | 6 [3–7] | 51 [23.5–86.5] | 163 [132–261.5] | ||||
Stage 3 | 109 [66–172] | 5 [3–8] | 21 [15–34] | 157 [103–216] | ||||
Stage 4 | 90.5 [53.8–167] | p = 0.151 | 5 [3–8] | p = 0.942 | 22 [11–34] | p = 0.027 | 126 [87–207.8] | p = 0.159 |
SCLC Stage at Diagnosis | ||||||||
Limited | 74.5 [45.3–132.5] | 8 [5–12] | 16 [7.5–25] | 98 [73–163.5] | ||||
Extensive | 75 [41.3–124.8] | p = 0.616 | 7 [4–10] | p = 0.158 | 15 [9–23] | p = 0.944 | 98 [65–156] | p = 0.546 |